MOTS-c vs SLU-PP-332
How MOTS-c and SLU-PP-332 compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
MOTS-c and SLU-PP-332 come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
MOTS-c vs SLU-PP-332, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | MOTS-c | SLU-PP-332 |
|---|---|---|
| What it is | Mitochondrial-derived peptide (a 16-amino-acid peptide encoded inside mitochondrial DNA) | Synthetic small-molecule pan-ERR agonist (not a peptide) |
| Class / category | Longevity / mitochondrial | Longevity / mitochondrial |
| Evidence tier | Animal-only · Unclear · none in humans | Animal-only · Helped · none in humans |
| Studied / approved for | Insulin sensitivity and metabolic health; Exercise capacity / physical performance; Healthy aging / longevity | Preclinical exercise-endurance research; Preclinical obesity and metabolic-syndrome research; Preclinical healthy-aging research |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 5 | No data |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | Yes — on the WADA prohibited list |
| Key risks | Human safety data on injected MOTS-c is essentially nonexistent. MOTS-c is a peptide your own mitochondria already make, but that does not tell us whether dosing extra of it is safe — the safety information that exists comes from short mouse studies, and there is no long-term human data. The most concrete real-world risk is the product itself: it is sold as an unregulated research chemical, so what's actually in a given vial — purity, true dose, sterility — rides on a vendor you're mostly trusting on faith. | SLU-PP-332 has no human safety dataset: no clinical adverse-event rates, safe dose, contraindications, interaction studies, or long-term follow-up. Short mouse experiments cannot settle those questions. Products sold online add separate identity, purity, and dose-accuracy risks because no FDA-approved formulation exists. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
MOTS-c vs SLU-PP-332: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
Which one fits your goal
These two overlap enough that the honest call comes down to your specific goal and how much human evidence you want before trying something. Compare the differences in the table above — there's no universal winner here.
References
- 1.MOTS-c — indexed research (PubMed, National Library of Medicine)
- 2.MOTS-c — registered clinical studies (ClinicalTrials.gov)
- 3.MOTS-c for improving insulin sensitivity in prediabetes — Phase 2 trial (NCT07505745)
- 4.Phase 1a/1b study of CB4211 in healthy adults and adults with nonalcoholic fatty liver disease (NCT03998514)
- 5.CohBar topline results from the Phase 1a/1b study of the MOTS-c analog CB4211
- 6.Alzheimer's Drug Discovery Foundation — MOTS-c evidence review